| HOME >> BIOLOGY >> TECHNOLOGY |
Other current liabilities 565 -- --
--------- --------- ---------
Total current liabilities 4,094 3,104 3,402
--------- --------- ---------
LIABILITY IN RESPECT OF EMPLOYEE
SEVERANCE OBLIGATIONS 188 444 340
DEFERRED GAIN 198 598 398
COMMITMENTS AND CONTINGENCIES
--------- --------- ---------
Total liabilities 4,480 4,146 4,140
--------- --------- ---------
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.02 par value
(authorized 300,000,000 as of June
30, 2007, June 30, 2006 and
December 31, 2006, issued and
Outstanding 220,154,349,
220,069,801 and 220,124,349 as of
June 30, 2007, June 30, 2006 and
December 31, 2006, respectively) 1,072 1,072 1,072
Additional paid in capital 137,583 135,667 136,611
Deficit accumulated during the
development stage (129,572) (107,082) (114,923)
--------- --------- ---------
Total shareholders' equity 9,083 29,657 22,760
--------- --------- ---------
Total liabilities and shareholders'
equity 13,563 33,803 26,900
========= ========= =========
Interim Consolidated Statements of Operations for the Six
Months Ended June 30, 2007 and 2006 (unaudited)
(in thousa
'/>"/>
SOURCE XTL Biopharmaceuticals Ltd![]() Copyright©2007 PR Newswire. |